Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib and Brain Radiotherapy in NSCLC Brain Metastases
NCT01763385Phase 2Unknown
- Sponsor
- Wu Jieping Medical Foundation
- Start
- Nov 2012
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Wu Jieping Medical Foundation. Status: unknown.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01763385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01763385.